Colectomy rate comparison after treatment of ulcerative colitis with placebo or infliximab.
about
Adverse effects of biologics: a network meta-analysis and Cochrane overviewInflammatory bowel disease surgery in the biologic eraImpact of thiopurines and anti-tumour necrosis factor therapy on hospitalisation and long-term surgical outcomes in ulcerative colitisDisease monitoring in inflammatory bowel diseasePharmacologic therapy for inflammatory bowel disease refractory to steroidsRole of surgery in severe ulcerative colitis in the era of medical rescue therapyGlucose intolerance and diabetes mellitus in ulcerative colitis: pathogenetic and therapeutic implicationsReview article: the role of anti-TNF in the management of ulcerative colitis -- past, present and futureClinical use and mechanisms of infliximab treatment on inflammatory bowel disease: a recent updateImpact of medical therapies on inflammatory bowel disease complication rateBiologics in the management of ulcerative colitis - comparative safety and efficacy of TNF-α antagonistsInflammatory pathways of importance for management of inflammatory bowel diseaseInfliximab is superior to other biological agents for treatment of active ulcerative colitis: A meta-analysisAn indirect comparison of infliximab versus adalimumab or golimumab for active ulcerative colitisReview article: dose optimisation of infliximab for acute severe ulcerative colitis.How do patients with inflammatory bowel disease want their biological therapy administered?Anti-TNF alpha in the treatment of ulcerative colitis: a valid approach for organ-sparing or an expensive option to delay surgery?Need for infliximab dose intensification in Crohn's disease and ulcerative colitis.Current status of monoclonal antibody therapy for the treatment of inflammatory bowel disease.The London Position Statement of the World Congress of Gastroenterology on Biological Therapy for IBD with the European Crohn's and Colitis Organization: when to start, when to stop, which drug to choose, and how to predict response?Management of acute severe ulcerative colitis.Current and emerging biologics for ulcerative colitis.Current and emerging drugs for the treatment of inflammatory bowel disease.Colectomy is a risk factor for venous thromboembolism in ulcerative colitis.Cause for controversy? Infliximab in the treatment of ulcerative colitis: an update.New strategies for treatment of inflammatory bowel diseaseManagement of arthropathy in inflammatory bowel diseases.Pros and cons of medical management of ulcerative colitis.Anti-tumour necrosis factor agent and liver injury: literature review, recommendations for management.Severe Henoch-Schönlein purpura with infliximab for ulcerative colitisInflammatory bowel disease associated arthropathyOutcomes after escalation of infliximab therapy in ambulatory patients with moderately active ulcerative colitisPatterns of Antibiotic Exposure and Clinical Disease Activity in Inflammatory Bowel Disease: A 4-year Prospective Study.Thirty-day mortality after elective and emergency total colectomy in Danish patients with inflammatory bowel disease: a population-based nationwide cohort studyReview article: the practical management of acute severe ulcerative colitis.Infliximab versus Cyclosporine Treatment for Severe Corticosteroid-Refractory Ulcerative Colitis: A Korean, Retrospective, Single Center Study.Histological healing after infliximab induction therapy in children with ulcerative colitisInfliximab-associated fulminant hepatic failure in ulcerative colitis: a case report.Cost-effectiveness of adalimumab, infliximab or vedolizumab as first-line biological therapy in moderate-to-severe ulcerative colitisNon-adherence to Anti-TNF Therapy is Associated with Illness Perceptions and Clinical Outcomes in Outpatients with Inflammatory Bowel Disease: Results from a Prospective Multicentre Study.
P2860
Q24234197-AD73C3C8-A20A-43A4-BBEA-51652ECB30A5Q26745627-48967A80-2F53-482F-9FB3-DDCD8ED471EFQ26771136-9A346D28-83A7-40B6-A6ED-5BA787465EF7Q26777553-5CFB4D8F-FEC7-4203-9C78-CBC50F81540DQ26796415-28673C31-A8C9-4848-BF2F-0B08841C6940Q26830235-6483B7FE-40A6-4A14-9D6E-741D1E162C30Q26866110-652536CA-48F7-4BE7-B857-297EF26E9CDAQ26992012-BD3EDED1-5E1B-4DDD-8E8C-A305535B9C97Q26994776-14F4EC22-3E07-4CED-9460-9372BAF8254CQ26995479-7B774543-46C2-479F-A768-027C5E0D5037Q26999078-B6628CD2-46EF-41E6-AF8A-517B00296CD3Q27005445-9373B771-0DF7-4972-9ECA-6C99E88C2209Q27006683-B7B4B3C5-12FB-477E-BA91-548913731F7DQ28079322-1A3EBD65-5239-42FD-BADE-4175E85E993BQ30239077-1120EDC6-AD9E-4BE9-BC06-6B1BB9F72B3CQ33523157-962217A0-D948-4C40-BE98-169223FD9F28Q33564081-62A0E98E-14FC-456C-8250-373F389B5A91Q33958740-2E251DF4-61A0-4875-BB92-882514D3932BQ34127277-A7A5047D-4C93-4F04-968A-E2D938C7D9DEQ34147687-E882DF6E-C879-4657-A596-DAEE75F2DB18Q34508900-0F2A52C1-753A-429F-9B9B-DC3B420A6E11Q34809305-79C338A2-9918-49FE-8BB6-243A80F4ECCAQ34883210-57AFC438-BEDD-4CC9-B3FF-9BB6772B3804Q35012116-61915BFE-9138-48A3-AB52-4C2EA8780500Q35026302-12B06FE2-633E-42A4-B931-58F733BFBD00Q35069777-9F63AEA7-2BCE-4726-9844-81DBEB7C6034Q35091366-D0D3E60A-DDD3-4E88-8CE8-F5EB79CE109EQ35100726-66C051BF-7B95-4F57-B76F-A7D0B2FEE25AQ35526652-CFBE05BC-E22C-436A-A3B8-A2E985CD1021Q35625482-60AD4B06-14A2-493C-880A-3893408A3898Q35680638-63DBFF0F-25FC-4D87-BCFA-95050F660CE4Q35752240-202F4888-7331-451C-B66B-506C99DB421DQ35752421-9ECD6A74-9E8D-49A2-8969-D01EF0D49DF9Q35882026-45CDBA59-CFE4-4FFB-9E1A-035778CCB5CAQ35883580-20FE30E0-830D-46F6-B5DD-045181AA59CCQ36037115-89015C10-B8A1-41FD-8C1A-F7B2012255B4Q36105637-C46D3A55-9EB0-4CC8-AA00-43EC101C4A9CQ36232337-6CBA9E87-0D07-4470-B040-89CAD85D8EDBQ36882311-30944AC4-FBA4-4350-A429-19E7DBF84E44Q37118400-8ED033D9-2F2B-4B2F-907C-42A3D5D936A3
P2860
Colectomy rate comparison after treatment of ulcerative colitis with placebo or infliximab.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
2009年學術文章
@yue
2009年學術文章
@zh-hant
name
Colectomy rate comparison afte ...... is with placebo or infliximab.
@en
Colectomy rate comparison afte ...... is with placebo or infliximab.
@nl
type
label
Colectomy rate comparison afte ...... is with placebo or infliximab.
@en
Colectomy rate comparison afte ...... is with placebo or infliximab.
@nl
prefLabel
Colectomy rate comparison afte ...... is with placebo or infliximab.
@en
Colectomy rate comparison afte ...... is with placebo or infliximab.
@nl
P2093
P50
P1433
P1476
Colectomy rate comparison afte ...... is with placebo or infliximab.
@en
P2093
Allan Olson
Bruce E Sands
Daniel Present
Daniel Rachmilewitz
Gary R Lichtenstein
Jewel Johanns
Jiandong Lu
Kevin Horgan
Stephen B Hanauer
Walter Reinisch
P304
1250-60; quiz 1520
P356
10.1053/J.GASTRO.2009.06.061
P407
P577
2009-07-28T00:00:00Z